Millennium Management’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-100,000
Closed -$3.55M – 5805
2025
Q4
$3.55M Sell
100,000
-90,100
-47% -$2.53M ﹤0.01% 3387
2025
Q3
$2.73M Buy
190,100
+113,200
+147% +$1.34M ﹤0.01% 3754
2025
Q2
$552K Buy
76,900
+26,900
+54% +$149K ﹤0.01% 4839
2025
Q1
$300K Sell
50,000
-50,000
-50% -$392K ﹤0.01% 5103
2024
Q4
$780K Buy
+100,000
New +$997K ﹤0.01% 4399
2024
Q3
– Sell
-29,100
Closed -$245K – 6143
2024
Q2
$245K Sell
29,100
-49,400
-63% -$375K ﹤0.01% 5027
2024
Q1
$528K Buy
+78,500
New +$485K ﹤0.01% 4772

Other funds holding COGT

Millennium Management's COGT Position: Q3 2026 in Review

Millennium Management reduced its Cogent Biosciences (COGT) stake by 64% in Q3 2026, selling an estimated $21.5M and leaving 324,672 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2256.

Millennium Management first reported a position in COGT in Q1 2018 and has held it in 29 quarters since. The position peaked at $45.9M in Q1 2026. 316 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Millennium Management held 324,672 shares of Cogent Biosciences worth $10.4M as of Q3 2026.
  • Millennium Management sold 583,040 Cogent Biosciences shares in Q3 2026, an estimated $21.5M.
  • Cogent Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q3 2026, its #2256 holding.
  • Millennium Management first reported a position in Cogent Biosciences in Q1 2018 and has held it in 29 quarters since.
  • Millennium Management's Cogent Biosciences position peaked at $45.9M in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.